Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts.

Author information

ORCIDs linked to this article

The EMBO Journal, 01 May 1987, 6(5):1281-1286
https://doi.org/10.1002/j.1460-2075.1987.tb02365.x PMID: 3111844 PMCID: PMC553930

Free full text in Europe PMC

Abstract 

We have studied the mechanism of a transforming growth factor-beta (TGF-beta)-stimulated production of type-1 plasminogen activator inhibitor (PAI-1) in WI-38 human lung fibroblasts. TGF-beta causes an early increase in the PAI-1 mRNA level which reaches a maximal 50-fold enhancement after 8 h. Blocking of protein synthesis with cycloheximide causes an equally strong increase in the level of PAI-1 mRNA. Quantitative studies of the effect of TGF-beta on PAI-1 protein levels in cell extracts and culture media by using monoclonal antibodies are consistent with the effect on PAI-1 mRNA. The results suggest a primary effect of TGF-beta on PAI-1 gene transcription, and also suggest the possibility that the transcription of this gene in non-induced cells may be suppressed by a short-lived negatively regulating protein. Urokinase-type (u-PA) and tissue-type (t-PA) plasminogen activators are decreased in the culture media of TGF-beta-treated cells concomitantly with the increase in PAI-1 accumulation. These findings show that a primary and important biological effect of TGF-beta may be an overall decreased extracellular proteolytic activity, and give an insight into the molecular mechanisms underlying TGF-beta action at the genetic level.

Free full text 

Logo of embojLink to Publisher's site
EMBO J. 1987 May; 6(5): 1281–1286.
PMCID: PMC553930
PMID: 3111844

Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts.

L R Lund, A Riccio, P A Andreasen, L S Nielsen, P Kristensen, M Laiho, O Saksela, F Blasi, and K Danø
Copyright and License information Disclaimer

Abstract

We have studied the mechanism of a transforming growth factor-beta (TGF-beta)-stimulated production of type-1 plasminogen activator inhibitor (PAI-1) in WI-38 human lung fibroblasts. TGF-beta causes an early increase in the PAI-1 mRNA level which reaches a maximal 50-fold enhancement after 8 h. Blocking of protein synthesis with cycloheximide causes an equally strong increase in the level of PAI-1 mRNA. Quantitative studies of the effect of TGF-beta on PAI-1 protein levels in cell extracts and culture media by using monoclonal antibodies are consistent with the effect on PAI-1 mRNA. The results suggest a primary effect of TGF-beta on PAI-1 gene transcription, and also suggest the possibility that the transcription of this gene in non-induced cells may be suppressed by a short-lived negatively regulating protein. Urokinase-type (u-PA) and tissue-type (t-PA) plasminogen activators are decreased in the culture media of TGF-beta-treated cells concomitantly with the increase in PAI-1 accumulation. These findings show that a primary and important biological effect of TGF-beta may be an overall decreased extracellular proteolytic activity, and give an insight into the molecular mechanisms underlying TGF-beta action at the genetic level.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 1281
1281
icon of scanned page 1282
1282
icon of scanned page 1283
1283
icon of scanned page 1284
1284
icon of scanned page 1285
1285
icon of scanned page 1286
1286
 

Images in this article

Fig. 1.
Fig. 1.
on p.1282
Fig. 3.
Fig. 3.
on p.1283
Fig. 6.
Fig. 6.
on p.1284
Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Andreasen PA, Nielsen LS, Grøndahl-Hansen J, Skriver L, Zeuthen J, Stephens RW, Danø K. Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. EMBO J. 1984 Jan;3(1):51–56. [Europe PMC free article] [Abstract] [Google Scholar]
  • Andreasen PA, Nielsen LS, Kristensen P, Grøndahl-Hansen J, Skriver L, Danø K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem. 1986 Jun 15;261(17):7644–7651. [Abstract] [Google Scholar]
  • Andreasen PA, Christensen TH, Huang JY, Nielsen LS, Wilson EL, Danø K. Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies. Mol Cell Endocrinol. 1986 May;45(2-3):137–147. [Abstract] [Google Scholar]
  • Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Danø K. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett. 1986 Dec 15;209(2):213–218. [Abstract] [Google Scholar]
  • Astedt B, Lecander I, Brodin T, Lundblad A, Löw K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemost. 1985 Feb 18;53(1):122–125. [Abstract] [Google Scholar]
  • Bonsall RW, Hunt S. Characteristics of interactions between surfactants and the human erythrocyte membrane. Biochim Biophys Acta. 1971 Oct 12;249(1):266–280. [Abstract] [Google Scholar]
  • BURTON K. A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J. 1956 Feb;62(2):315–323. [Europe PMC free article] [Abstract] [Google Scholar]
  • Chapman HA, Jr, Stone OL. Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor. Biochem J. 1985 Aug 15;230(1):109–116. [Europe PMC free article] [Abstract] [Google Scholar]
  • Coleman PL, Patel PD, Cwikel BJ, Rafferty UM, Sznycer-Laszuk R, Gelehrter TD. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352–4357. [Abstract] [Google Scholar]
  • Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980 Jun 18;43(2):77–89. [Abstract] [Google Scholar]
  • Crutchley DJ, Conanan LB. Endotoxin induction of an inhibitor of plasminogen activator in bovine pulmonary artery endothelial cells. J Biol Chem. 1986 Jan 5;261(1):154–159. [Abstract] [Google Scholar]
  • Danø K, Reich E. Serine enzymes released by cultured neoplastic cells. J Exp Med. 1978 Mar 1;147(3):745–757. [Europe PMC free article] [Abstract] [Google Scholar]
  • Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. [Abstract] [Google Scholar]
  • Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 1985 Aug 22;316(6030):701–705. [Abstract] [Google Scholar]
  • Erickson LA, Hekman CM, Loskutoff DJ. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci U S A. 1985 Dec;82(24):8710–8714. [Europe PMC free article] [Abstract] [Google Scholar]
  • Gelehrter TD, Barouski-Miller PA, Coleman PL, Cwikel BJ. Hormonal regulation of plasminogen activator in rat hepatoma cells. Mol Cell Biochem. 1983;53-54(1-2):11–21. [Abstract] [Google Scholar]
  • Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Dano K, Lebo RV, Gelehrter TD. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest. 1986 Dec;78(6):1673–1680. [Europe PMC free article] [Abstract] [Google Scholar]
  • Golder JP, Stephens RW. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators. Eur J Biochem. 1983 Nov 15;136(3):517–522. [Abstract] [Google Scholar]
  • Goustin AS, Leof EB, Shipley GD, Moses HL. Growth factors and cancer. Cancer Res. 1986 Mar;46(3):1015–1029. [Abstract] [Google Scholar]
  • Grimaldi G, Di Fiore P, Locatelli EK, Falco J, Blasi F. Modulation of urokinase plasminogen activator gene expression during the transition from quiescent to proliferative state in normal mouse cells. EMBO J. 1986 May;5(5):855–861. [Europe PMC free article] [Abstract] [Google Scholar]
  • Grøndahl-Hansen J, Ralfkiaer E, Nielsen LS, Kristensen P, Frentz G, Danø K. Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. J Invest Dermatol. 1987 Jan;88(1):28–32. [Abstract] [Google Scholar]
  • Guesdon JL, Ternynck T, Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem. 1979 Aug;27(8):1131–1139. [Abstract] [Google Scholar]
  • Ignotz RA, Massagué J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986 Mar 25;261(9):4337–4345. [Abstract] [Google Scholar]
  • Kopitar M, Rozman B, Babnik J, Turk V, Mullins DE, Wun TC. Human leucocyte urokinase inhibitor--purification, characterization and comparative studies against different plasminogen activators. Thromb Haemost. 1985 Dec 17;54(4):750–755. [Abstract] [Google Scholar]
  • Kristensen P, Larsson LI, Nielsen LS, Grøndahl-Hansen J, Andreasen PA, Danø K. Human endothelial cells contain one type of plasminogen activator. FEBS Lett. 1984 Mar 12;168(1):33–37. [Abstract] [Google Scholar]
  • Kruithof EK, Vassalli JD, Schleuning WD, Mattaliano RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem. 1986 Aug 25;261(24):11207–11213. [Abstract] [Google Scholar]
  • Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. [Abstract] [Google Scholar]
  • Laiho M, Saksela O, Keski-Oja J. Transforming growth factor beta alters plasminogen activator activity in human skin fibroblasts. Exp Cell Res. 1986 Jun;164(2):399–407. [Abstract] [Google Scholar]
  • Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J Cell Biol. 1986 Dec;103(6 Pt 1):2403–2410. [Europe PMC free article] [Abstract] [Google Scholar]
  • Leof EB, Proper JA, Getz MJ, Moses HL. Transforming growth factor type beta regulation of actin mRNA. J Cell Physiol. 1986 Apr;127(1):83–88. [Abstract] [Google Scholar]
  • Leof EB, Proper JA, Goustin AS, Shipley GD, DiCorleto PE, Moses HL. Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2453–2457. [Europe PMC free article] [Abstract] [Google Scholar]
  • Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci U S A. 1983 May;80(10):2956–2960. [Europe PMC free article] [Abstract] [Google Scholar]
  • Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 1981 Nov;41(11 Pt 1):4629–4636. [Abstract] [Google Scholar]
  • Loskutoff DJ, Edgington TS. An inhibitor of plasminogen activator in rabbit endothelial cells. J Biol Chem. 1981 May 10;256(9):4142–4145. [Abstract] [Google Scholar]
  • Loskutoff DJ, Roegner K, Erickson LA, Schleef RR, Huttenlocher A, Coleman PL, Gelehrter TD. The dexamethasone-induced inhibitor of plasminogen activator in hepatoma cells is antigenically-related to an inhibitor produced by bovine aortic endothelial cells. Thromb Haemost. 1986 Feb 28;55(1):8–11. [Abstract] [Google Scholar]
  • Medcalf RL, Richards RI, Crawford RJ, Hamilton JA. Suppression of urokinase-type plasminogen activator mRNA levels in human fibrosarcoma cells and synovial fibroblasts by anti-inflammatory glucocorticoids. EMBO J. 1986 Sep;5(9):2217–2222. [Europe PMC free article] [Abstract] [Google Scholar]
  • Mullins DE, Rohrlich ST. The role of proteinases in cellular invasiveness. Biochim Biophys Acta. 1983 Dec 29;695(3-4):177–214. [Abstract] [Google Scholar]
  • Nagamine Y, Pearson D, Altus MS, Reich E. cDNA and gene nucleotide sequence of porcine plasminogen activator. Nucleic Acids Res. 1984 Dec 21;12(24):9525–9541. [Europe PMC free article] [Abstract] [Google Scholar]
  • Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Danø K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry. 1982 Dec 7;21(25):6410–6415. [Abstract] [Google Scholar]
  • Nielsen LS, Hansen JG, Andreasen PA, Skriver L, Danø K, Zeuthen J. Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification. EMBO J. 1983;2(1):115–119. [Europe PMC free article] [Abstract] [Google Scholar]
  • Nielsen LS, Grøndahl-Hansen J, Andreasen PA, Skriver L, Zeuthen J, Danø K. Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. J Immunoassay. 1986;7(3):209–228. [Abstract] [Google Scholar]
  • Nielsen LS, Andreasen PA, Grøndahl-Hansen J, Huang JY, Kristensen P, Danø K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification. Thromb Haemost. 1986 Apr 30;55(2):206–212. [Abstract] [Google Scholar]
  • Ny T, Elgh F, Lund B. The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains. Proc Natl Acad Sci U S A. 1984 Sep;81(17):5355–5359. [Europe PMC free article] [Abstract] [Google Scholar]
  • Ny T, Bjersing L, Hsueh AJ, Loskutoff DJ. Cultured granulosa cells produce two plasminogen activators and an antiactivator, each regulated differently by gonadotropins. Endocrinology. 1985 Apr;116(4):1666–1668. [Abstract] [Google Scholar]
  • Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6776–6780. [Europe PMC free article] [Abstract] [Google Scholar]
  • Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld AJ, van Mourik JA. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J. 1986 Oct;5(10):2539–2544. [Europe PMC free article] [Abstract] [Google Scholar]
  • Philips M, Juul AG, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta. 1984 Nov 6;802(1):99–110. [Abstract] [Google Scholar]
  • Philips M, Juul AG, Thorsen S, Selmer J, Zeuthen J. Immunological relationship between the fast-acting plasminogen activator inhibitors from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta. Thromb Haemost. 1986 Apr 30;55(2):213–217. [Abstract] [Google Scholar]
  • Ponte P, Gunning P, Blau H, Kedes L. Human actin genes are single copy for alpha-skeletal and alpha-cardiac actin but multicopy for beta- and gamma-cytoskeletal genes: 3' untranslated regions are isotype specific but are conserved in evolution. Mol Cell Biol. 1983 Oct;3(10):1783–1791. [Europe PMC free article] [Abstract] [Google Scholar]
  • Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F. The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res. 1985 Apr 25;13(8):2759–2771. [Europe PMC free article] [Abstract] [Google Scholar]
  • Roberts AB, Anzano MA, Lamb LC, Smith JM, Frolik CA, Marquardt H, Todaro GJ, Sporn MB. Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF. Nature. 1982 Feb 4;295(5848):417–419. [Abstract] [Google Scholar]
  • Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A. 1985 Jan;82(1):119–123. [Europe PMC free article] [Abstract] [Google Scholar]
  • Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167–4171. [Europe PMC free article] [Abstract] [Google Scholar]
  • Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta. 1985 Nov 12;823(1):35–65. [Abstract] [Google Scholar]
  • Scott RW, Bergman BL, Bajpai A, Hersh RT, Rodriguez H, Jones BN, Barreda C, Watts S, Baker JB. Protease nexin. Properties and a modified purification procedure. J Biol Chem. 1985 Jun 10;260(11):7029–7034. [Abstract] [Google Scholar]
  • Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature. 313(6005):745–747. [Abstract] [Google Scholar]
  • Sporn MB, Roberts AB, Wakefield LM, Assoian RK. Transforming growth factor-beta: biological function and chemical structure. Science. 1986 Aug 1;233(4763):532–534. [Abstract] [Google Scholar]
  • Sprengers ED, Verheijen JH, Van Hinsbergh VW, Emeis JJ. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim Biophys Acta. 1984 Sep 28;801(2):163–170. [Abstract] [Google Scholar]
  • Stoppelli MP, Verde P, Grimaldi G, Locatelli EK, Blasi F. Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate. J Cell Biol. 1986 Apr;102(4):1235–1241. [Europe PMC free article] [Abstract] [Google Scholar]
  • Sullivan LM, Quigley JP. An anticatalytic monoclonal antibody to avian plasminogen activator: its effect on behavior of RSV-transformed chick fibroblasts. Cell. 1986 Jun 20;45(6):905–915. [Abstract] [Google Scholar]
  • Wiman B, Chmielewska J, Rånby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem. 1984 Mar 25;259(6):3644–3647. [Abstract] [Google Scholar]
Articles from The EMBO Journal are provided here courtesy of Nature Publishing Group

Full text links 

Read article at publisher's site: https://doi.org/10.1002/j.1460-2075.1987.tb02365.x

Read article for free, from open access legal sources, via Unpaywall: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/j.1460-2075.1987.tb02365.xUnpaywall

Citations & impact 

Impact metrics

158
Citations
Jump to Citations

Citations of article over time

Article citations

Go to all (158) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.